Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effects of leflunomide in treating African-American and
European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to
decrease the body's immune response and may delay the symptoms of multiple myeloma in
patients of African-American and European decent.